Efficacy and Safety Data for ZOSTAVAX® (Zoster Vaccine Live), Merck & Co., Inc. (MRK)'s Shingles Vaccine, in Adults Ages 50 to 59 Published in Clinical Infectious Diseases
4/2/2012 10:15:58 AM
WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, announced today that data from the pivotal Phase III study with ZOSTAVAX® (Zoster Vaccine Live) in adults ages 50 to 59 were published in the April 1 issue of Clinical Infectious Diseases. In this study, ZOSTAVAX, Merck's vaccine for the prevention of herpes zoster, commonly known as shingles, significantly reduced the risk of developing shingles by nearly 70 percent in adults ages 50 to 59, compared with placebo. The results from this study provided the data that supported the U.S. Food and Drug Administration’s (FDA) expanded indication for ZOSTAVAX in March 2011 in this age group. ZOSTAVAX is the only shingles vaccine licensed for use in the United States.